Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Health Research Projects (NSERC partnered)

University of Toronto

$287,484.00

High-throughput screening of cell contraction for applications in regenerative medicine and drug testing

FY 2011-12

Summary
"We will develop and test a novel method to quantify the contractile activity of cultured cells that will be established as a high throughput screening (HTS) format for industrial applications. HTS quantification of cell contraction is a pivotal yet not available functional test with important fields of application: 1) Functional contraction tests for mesenchymal stem cells to be used to enhance tissue repair, e.g., chronic wound healing associated with diabetes (>3 Mio Canadians, ~13 Bio $) or to regenerate diseased cardiovascular tissues (>10 Mio Canadians, ~18 Bio $). 2) HTS of drugs to tune cell contractility in the cardiovascular system, in fibrosis and in cancer research. We have recently developed a novel rubber polymer that allows optical analysis of cell contraction. Essential improvements over existing deformable culture substrates can turn the new material into a widely-used assay: a) it can be provided in any cell culture format; b) it can be tuned to respond to the specific requirements and force levels of different cell types; c) it is compatible with all standard biochemical and genetic tests; d) it has superb optical properties, and e) it has ideal storing and shipping properties. We will pursue two main objectives: 1) To upgrade our technology for ready-to-use applications, we will apply novel protocols to promote cell adhesion, enable automated analysis, and tune substrates to specific cell types of industrial interest. 2) To translate the technology to a HTS format for industrial use, we will establish multi-well HTS wrinkling plates. With support from our company partners and profiting from our own expertise, we will apply our HTS system to industrially relevant fields: mesenchymal stem cell therapy, anti-fibrosis and anti-cancer drug testing. Together, contraction-associated diseases represent a hundreds of Bio $ burden for the Canadian healthcare system. Providing for the first time an HTS in vitro contraction test will result in dramatically reduced costs for Canadian health care and drug development."
Program
Collaborative Health Research Projects (NSERC partnered)
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
248254
Name
Hinz Boris
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Natural Sciences and Engineering Research Council of Canada (NSERC)
Prcname2
Collaborative Health Research Projects - NSERC Partnered
Projecttitle
High-throughput screening of cell contraction for applications in regenerative medicine and drug testing
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$287,484
Cihrequipment2
$0
Programname2
Collaborative Health Research Projects (NSERC partnered)
Keyworddelim
Biomaterials; Cardiomyocytes; Cardiovascular Diseases; Cell Contraction; Fibrosis; High Throughput Drug Screening; Myofibrolasts; Regenerative Medicine; Technological Development; Wound Healing
Abstract
"We will develop and test a novel method to quantify the contractile activity of cultured cells that will be established as a high throughput screening (HTS) format for industrial applications. HTS quantification of cell contraction is a pivotal yet not available functional test with important fields of application: 1) Functional contraction tests for mesenchymal stem cells to be used to enhance tissue repair, e.g., chronic wound healing associated with diabetes (>3 Mio Canadians, ~13 Bio $) or to regenerate diseased cardiovascular tissues (>10 Mio Canadians, ~18 Bio $). 2) HTS of drugs to tune cell contractility in the cardiovascular system, in fibrosis and in cancer research. We have recently developed a novel rubber polymer that allows optical analysis of cell contraction. Essential improvements over existing deformable culture substrates can turn the new material into a widely-used assay: a) it can be provided in any cell culture format; b) it can be tuned to respond to the specific requirements and force levels of different cell types; c) it is compatible with all standard biochemical and genetic tests; d) it has superb optical properties, and e) it has ideal storing and shipping properties. We will pursue two main objectives: 1) To upgrade our technology for ready-to-use applications, we will apply novel protocols to promote cell adhesion, enable automated analysis, and tune substrates to specific cell types of industrial interest. 2) To translate the technology to a HTS format for industrial use, we will establish multi-well HTS wrinkling plates. With support from our company partners and profiting from our own expertise, we will apply our HTS system to industrially relevant fields: mesenchymal stem cell therapy, anti-fibrosis and anti-cancer drug testing. Together, contraction-associated diseases represent a hundreds of Bio $ burden for the Canadian healthcare system. Providing for the first time an HTS in vitro contraction test will result in dramatically reduced costs for Canadian health care and drug development."
Competitiondate
201110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Hinz, Boris
Approvedterm
3 ans 0 mois
Cihrcontribution2
Inst of Musculoskel Hlth &Arth~ $75,000~ $0~Knowledge Translation Branch~ $212,484~ $0~
University of Toronto - $287,484 Grant (2011-12) | Canada Spends